Activities

Expand all
Social Determinants of Health Through a Gout Lens
GLP-1 Agonists: What Rheumatologists & Endocrinologists Need to Know

Activity Overview

This recorded webinar explores the expanding role of glucagon-like peptide-1 receptor agonists beyond diabetes and obesity, with a focus on their relevance in rheumatology care. Designed for rheumatologists, endocrinologists, pharmacists, advanced practice providers, and primary care clinicians, the session examines the intersection of metabolic disease and inflammatory conditions through a case-based, clinically practical lens. Key themes include glucagon-like peptide-1 receptor agonists, rheumatology, obesity, inflammatory arthritis, osteoarthritis, metabolic disease, interdisciplinary care, pharmacotherapy, access, safety, ethics, and clinical decision-making.

Through expert-led presentations, this activity highlights emerging evidence and practical applications in rheumatic disease.

Speaker Bios

Thomas Appleton, MD, PhD, FRCPC, is passionate about rheumatology research, communication, and clinical care. He is Division Head of Rheumatology at St. Joseph’s Health Care London and Western University in London, Canada. As a clinician scientist, his research focuses the of resolution of inflammation in osteoarthritis and inflammatory arthritis. Dr. Appleton is a past director of the Ontario Rheumatology Association (ORA) and past chair of the Canadian Rheumatology Association (CRA) Scientific Committee. He now serves as an advisor to Arthritis Society Canada and chair of the ORA Informatics Committee where he leads the RheumView project, developing digital health and AI health solutions for clinical informatics.

Dr. Bharati Bhardwaja, PharmD, BCPS, LSSBB, is a clinical pharmacist, healthcare leader, educator, and researcher with more than 24 years of experience at Kaiser Permanente Colorado, where she serves as the Rheumatology Clinical Pharmacist. She has led the development and expansion of innovative clinical pharmacy services, spearheaded multidisciplinary quality and safety initiatives and played a pivotal role in implementing evidence-based care models in rheumatology. Beyond her clinical practice, Dr. Bhardwaja is an active leader and volunteer within the rheumatology community. She serves in multiple leadership roles with ACR and ARP contributes to strategic planning and special projects, and supports education through national presentations, mentoring, and precepting pharmacy residents and students. A published author and recipient of numerous awards recognizing excellence in patient safety, quality improvement, and residency precepting, she is passionate about advancing pharmacy practice through collaboration, innovation, and leadership. Her work is dedicated to improving patient outcomes while empowering healthcare teams to deliver high-quality, evidence-based care.

Dimpi Nitin Desai, MD, is a Clinical Associate Professor in the Division of Endocrinology, Gerontology, and Metabolism at Stanford University School of Medicine, where she also serves as Associate Program Director of the Endocrinology Fellowship Program. She is an endocrinologist and obesity medicine specialist whose clinical, research, and educational work is dedicated to advancing the care of people living with obesity and its metabolic complications. Dr. Desai specializes in the comprehensive management of obesity and obesity-related diseases, with expertise in complex obesity, type 1 and type 2 diabetes, MASLD, post-bariatric care, and other obesity-associated comorbidities. Her work emphasizes evidence-based, patient-centered, and compassionate long-term obesity care. She holds several national leadership positions within leading endocrine and obesity organizations. She serves on the Endocrine Society Guideline Development Panel for the pharmacologic management of obesity, is Co-Chair of the Endocrine Society Obesity Fellows Program, and is Chair-Elect of the Clinical Practice Section of The Obesity Society. Through these roles, she is actively involved in advancing obesity education, clinical practice, and guideline development. An internationally invited speaker, Dr. Desai has delivered numerous lectures and educational programs on obesity medicine, diabetes, and metabolic health. Her academic interests include improving access to obesity care, medical education, multidisciplinary management of obesity, and translating emerging evidence into practical strategies that improve patient outcomes.

Rouhin Sen, MD, MS, is an Assistant Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB), where he also serves as an Associate Scientist in both the Center for Outcomes and Effectiveness Research and Education (COERE) and the Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity Center (CAMBAC). Dr. Sen completed his rheumatology fellowship at the University of Colorado after serving as Chief Medical Resident at Creighton University Medical Center. His clinical and research interests focus on spondyloarthritis, with an emphasis on biomarkers, genetic epidemiology, and cardiovascular outcomes. He is the principal investigator on federally and institutionally funded studies investigating cardiovascular risk in spondyloarthritis and has authored numerous peer-reviewed publications in the field. Dr. Sen is an active member of the ACR and serves on the ACR guideline development panels for psoriatic arthritis and axial spondyloarthritis. He is also recognized for excellence in teaching and patient care, receiving UAB's Teaching Excellence Award and multiple Top Tier Patient Experience honors.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the metabolic and systemic mechanisms of GLP-1 receptor agonists relevant to rheumatology patients

  • Evaluate emerging evidence in osteoarthritis, inflammatory arthritis, and comorbid conditions

  • Identify appropriate patient candidates and interdisciplinary care considerations

  • Review safety concerns relevant to GLP-1 and GLP-1/GIP agonists

  • Provide a high-level overview of Medicare GLP-1 Bridge program and medication access considerations

  • Apply case-based framework to optimize prescribing decisions


Target Audience

Advanced practice nurses, dieticians, endocrinologists, health service researchers, nurses, occupational therapists, pharmacists, primary care providers, physical therapists, physician assistants, rheumatologists, and rheumatology interprofessionals.


Price

Registration is complimentary.


Credit Information

This activity is not eligible for credit.


Acknowledgement of Commercial Support

The American College of Rheumatology and the Endocrine Society gratefully acknowledge Eli Lilly and Company for providing financial sponsorship for this educational activity.

Sponsorship is for acknowledgment purposes only. The sponsor had no role in the selection of faculty or the development, review, or presentation of the educational content.


Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.

PRSYM Highlights 2026

Activity Overview

The Pediatric Rheumatology Symposium (PRSYM) Highlights will provide up-to-date, practical clinical information and basic science knowledge on the diagnosis and management of pediatric patients with rheumatic diseases and immune disorders.

Topics

Addressing Key Issues in Pediatric Rheumatology 

Clinical Management

  • Harnessing AI
    Bella Mehta, MD

  • From Promise to Practice: The Evolving Biosimilar Landscape in Pediatric Rheumatology
    Ingrid Pan, PharmD

  • What Do We Know About Vaccinations in Kids with Inflammatory Rheumatic Diseases?
    Merav Heshin-Bekenstein, MD

Systemic Lupus Erythematosus

Juvenile Idiopathic Arthritis

  • Not So Silent After All—Demystifying the Temporomandibular Joint
    Marinka Twilt, MD, PhD, MSc 

  • From Clues to Clarity: Axial Disease in Juvenile Spondyloarthritis
    Pam Weiss, MD

  • Imaging as a Biomarker: Peripheral Joint Insights in JIA
    Patricia Vega-Fernandez, MD, RhMSUS, MSc 

  • Panel Discussion
    Pam Weiss, MD; Marinka Twilt, MD, PhD, MSc; Patricia Vega-Fernandez, MD, RhMSUS, MSc

Clinical Update - Guidelines & Recommendations

  • Uveitis: Clinical Trials & PROs
    Sheila Angeles Han, MD, MSc 

  • Mental Health Guidance Statements
    Tamar Rubinstein, MD, MS 

Juvenile Dermatomyositis and Scleroderma 

Vasculitis

  • Advancing Pediatric ANCA-Associated Vasculitis: Insights from Collaborative Research and Emerging Clinical Data
    Jessica Bloom, MD, MS

  • Renal Disease and Risk Stratification in Pediatric ANCA-associated Vasculitis (AAV)—Insights from the Pediatric Vasculitis Initiative
    Kelly Brown, PhD

QI/Implementation

Systemic Juvenile Idiopathic Arthritis


Target Audience

Rheumatologists, rheumatology interprofessionals, fellows in training, and residents.


Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Discuss the most up-to-date clinical information on the diagnosis and management of pediatric patients with rheumatic and immunologic disorders

  • Describe the most current information regarding the pathophysiology underlying pediatric rheumatic disorders

Price

  • ACR Member: $650

  • ARP Member: $325

  • ACR/ARP Student/Transitional Member: $325

  • ACR Nonmember: $1,300

  • ARP Nonmember: $650

If you are not a member, consider joining ACR/ARP.


CE & MOC Information

  • Credit must be claimed by March 30, 2029, at 11:59 PM ET.

  • By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board. 

  • After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM and/or ABP diplomates to the ABIM diplomate number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.

  • The following credit types must be self-reported to the appropriate board: CME, AAPA, AANC, AWSB ACE, and APA. The certificate is a record of your activity completion.

  • All participating healthcare professionals should claim only the credit commensurate with the extent of their participation in this activity.

Available Credit

  • CME: 13.00 AMA PRA Category 1 Credit(s)™

  • ABIM MOC: 13.00 Medical Knowledge Points

  • ABP MOC: 13.00 Lifelong Learning Points

Designation Statements

Joint Accreditation

In support of improving patient care, the American College of Rheumatology (ACR) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797

See the ACR’s CE Mission Statement. For more information, download the AMA PRA Booklet.

AMA

The American College of Rheumatology designates this enduring material for a maximum of 13.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program and American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM and ABP MOC credit.


Financial Relationship Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

  1. Advisor or review panel member

  2. Consultant

  3. Employee

  4. Officer or Board Member

  5. Grant/research support

  6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness

  7. Independent contractor

  8. Executive role and/or ownership interest

  9. Royalties and/or patent beneficiary

  10. Intellectual property/patents

  11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan

  12. Private investigator

  13. Expert witness

  14. Equity interest

  15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. PRSYM Highlights 2026 Financial Relationship Disclosures


Acknowledgement of Commercial Support

No commercial support was provided for this activity.


Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.

ACR Convergence 2026 On Demand

Activity Overview

ACR Convergence 2026 On Demand features recorded sessions from the premier international rheumatology meeting that took place in Chicago, Illinois. See cutting-edge insights across basic and clinical science with flexible, self-paced access to plenaries and symposia. 

Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.


Target Audience

Advanced practice nurses, counselors, dietitians, division directors, epidemiologists, fellows in training, health service researchers, nurses, occupational therapists, office managers/staff, pharmacists, practice administrators, primary care providers, physical therapists, physician associates, program directors, psychologists, researchers, residents, rheumatologists, rheumatology interprofessionals, social workers / community health workers, and students.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess their knowledge and competence in various rheumatic diseases and conditions

  • Support their skills in evaluating and diagnosing patients with rheumatic diseases

  • Discuss and collaborate on challenging cases with peers

  • Analyze emerging trends and technologies in rheumatology

  • Employ evidence-based approaches for managing rheumatic conditions

  • Identify new approaches and strategies for patient management

  • Interpret recent clinical trial and research findings

  • Apply new information from basic and clinical science to improve the care of people with rheumatologic illness


CE & MOC

In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797

See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet. 

Credit must be claimed by October 24, 2026, at 11:59 PM ET.

By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board. 

After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for diplomates to the diplomate number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to physician portals. Please allow at least 48 hours for points to display in the portal. 

AMA Designation Statement

The American College of Rheumatology designates this Enduring Material for a maximum of 210.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Recognition Statement: American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 210.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MOC Recognition Statement: American Board of Pediatrics (ABP)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 210.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.


Financial Relationship Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

  1. Advisor or review panel member

  2. Consultant

  3. Employee

  4. Officer or Board Member

  5. Grant/research support

  6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness

  7. Independent contractor

  8. Executive role and/or ownership interest

  9. Royalties and/or patent beneficiary

  10. Intellectual property/patents

  11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan

  12. Private investigator

  13. Expert witness

  14. Equity interest

  15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence 2025 On Demand Financial Relationship Disclosures


Acknowledgement of Commercial Support

No commercial support was provided for this activity.


Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.